Oruka Therapeutics, Inc.
ORKA
Classificação em ações
#3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Preço da ação
$81.40
Valor de mercado
$5.39B
Variação (1 dia)
1.86%
Variação (1 ano)
205.46%
País
US
Negociar Oruka Therapeutics, Inc. (ORKA)
Categoria
Healthcare
Lucros da Oruka Therapeutics, Inc. (ORKA)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Oruka Therapeutics, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Oruka Therapeutics, Inc. de 2005 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2025 | $-105.43M | 25.93% |
| 2024 | $-83.72M | 1,468.16% |
| 2023 | $-5.34M | -46.21% |
| 2022 | $-9.93M | -48.63% |
| 2021 | $-19.32M | 98.24% |
| 2020 | $-9.75M | 72.54% |
| 2019 | $-5.65M | -29.07% |
| 2018 | $-7.96M | -57.07% |
| 2017 | $-18.55M | 12.81% |
| 2016 | $-16.44M | 43.68% |
| 2015 | $-11.45M | 18.12% |
| 2014 | $-9.69M | 39.63% |
| 2013 | $-6.94M | 60.63% |
| 2012 | $-4.32M | -19.46% |
| 2011 | $-5.36M | -36.29% |
| 2010 | $-8.42M | -26.26% |
| 2009 | $-11.42M | -41.23% |
| 2008 | $-19.43M | 57.96% |
| 2007 | $-12.30M | -90.74% |
| 2006 | $-132.78M | 85.41% |
| 2005 | $-71.61M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
